Cellectis SA
CLLS
View Detailed Chart
3.167USD
+0.087+2.83%
Market hours （ET）Quotes delayed by 15 min
229.06MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+2.83%
5 Days
+3.84%
1 Month
+11.13%
6 Months
+158.54%
Year to Date
+75.95%
1 Year
+35.35%
View Detailed Chart
TradingKey Stock Score
Currency: USD Updated：2025-09-17Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
7
analysts
Buy
Current Rating
5.167
Target Price
+63.50%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Company Highlights
StrengthsRisks
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 91.32% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 49.22M.
Undervalued
The company’s latest PE is -5.30, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 18.10M shares, decreasing 11.99% quarter-over-quarter.
Held by Baillie Gifford
Star Investor Baillie Gifford holds 0.00 shares of this stock.
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.
Ticker SymbolCLLS
CompanyCellectis SA
CEODr. David Sourdive, Ph.D.
Websitehttps://www.cellectis.com/
Related Instruments
-1.91%
-0.72%
+3.03%
+1.45%
-0.23%
-2.47%
+0.66%
+0.84%
+3.93%
+1.95%
-0.72%
-0.22%
+2.57%
+0.77%
+2.31%
+0.70%
+5.49%
+2.85%
0.00%
+2.47%
